{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:20:05Z","timestamp":1791357605007,"version":"4.3.1"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Alcohol use disorder (AUD) is common in hospital patients. AUD medications are not typically initiated in that setting. The comparative effectiveness between initiation of oral naltrexone and extended-release injectable naltrexone in the hospital is not known.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the effectiveness of initiating oral naltrexone vs extended-release injectable naltrexone on reduction in alcohol use and health care utilization among medical inpatients with AUD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Alcohol Disorder Hospital Treatment (ADOPT) study is a randomized clinical trial conducted at an urban teaching hospital in the US, with enrollment between June 2016 and March 2020. Inpatients were screened for eligibility, and those with AUD and recent heavy drinking (defined as 5 or more drinks for men and 4 or more drinks for women) were enrolled. Outcomes were assessed at 3-month follow-up; assessors were not blinded to treatment assignment. Data were analyzed from May 2021 to September 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Participants received either daily oral naltrexone or monthly extended-release injectable naltrexone. All received medical management with a research nurse who specialized in addiction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Measures and Outcomes<\/jats:title><jats:p>The primary outcome was change in percentage of heavy drinking days (HDDs) over the past 30 days from baseline to 3-month follow-up, assessed by validated instrument. The secondary outcome was any acute health care utilization (emergency department or hospitalization) at 3-month follow-up over the past 90 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 248 participants, 199 (80.2%) were male, and the mean (SD) age was 49.4 (10.4) years. The baseline median (IQR) percentage of HDDs in the past 30 days was 80.0% (43.3-100). At 3-month follow-up, the mean percentage of HDDs in the past 30 days was reduced in both groups (oral naltrexone: baseline, 66.7% HDDs; 3-month follow-up, 27.4% HDDs; difference, \u221238.4 percentage points; 95% CI, \u2212125.0 to 48.2; extended-release injectable naltrexone: baseline, 70.7% HDDs; 3-month follow-up, 23.8% HDDs; difference, \u221246.4 percentage points; 95% CI, \u2212123.4 to 30.6; <jats:italic>P<\/jats:italic>\u2009=\u2009.14). At follow-up, 59 of 109 in the oral naltrexone arm (54.1%) and 66 of 108 in the extended-release injectable naltrexone arm (61.1%) reported acute health care utilization in the prior 3 months; the odds of this utilization were not significantly different between groups (adjusted odds ratio, 1.34; 95% CI, 0.77-2.33).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this randomized clinical trial, when initiated at hospital discharge, oral and extended-release injectable naltrexone did not differ in effectiveness. Participants had substantial reductions in HDDs in both treatment groups; however, there was not a significant difference in the reduction of percentage of HDDs in the past 30 days or acute health care utilization between groups. Hospitalization represents an opportunity to start AUD pharmacotherapy; choice of oral naltrexone vs extended-release injectable naltrexone should be directed by factors such as patient preference and insurance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02478489\">NCT02478489<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.0522","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:31:17Z","timestamp":1745249477000},"page":"635","source":"Crossref","is-referenced-by-count":20,"title":["Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder"],"prefix":"10.1001","volume":"185","author":[{"given":"Kara M.","family":"Magane","sequence":"first","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Dukes","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fielman","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor P.","family":"Palfai","sequence":"additional","affiliation":[{"name":"Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Regan","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts"},{"name":"South Shore Hospital, South Weymouth, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie M.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts"},{"name":"Center for Health Data Science, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Lee","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston Massachusetts"},{"name":"Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Kraemer","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Bullard","sequence":"additional","affiliation":[{"name":"Center for Health Data Science, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara A.","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Health Data Science, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts"},{"name":"Section of General Internal Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston Massachusetts"},{"name":"Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, Massachusetts"},{"name":"Grayken Center for Addiction, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"ioi250012r2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/acer.14609","article-title":"A cascade of care for alcohol use disorder: Using 2015-2019 National Survey on Drug Use and Health data to identify gaps in past 12-month care.","volume":"45","author":"Mintz","year":"2021","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"ioi250012r3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/014107680209500208","article-title":"Alcohol abuse: prevalence and detection in a general hospital.","volume":"95","author":"Hearne","year":"2002","journal-title":"J R Soc Med"},{"issue":"8","key":"ioi250012r4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.7326\/M23-0641","article-title":"Pharmacologic treatment initiation among Medicare beneficiaries hospitalized with alcohol use disorder.","volume":"176","author":"Bernstein","year":"2023","journal-title":"Ann Intern Med"},{"issue":"3","key":"ioi250012r6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11606-014-2968-9","article-title":"An inpatient treatment and discharge planning protocol for alcohol dependence: efficacy in reducing 30-day readmissions and emergency department visits.","volume":"30","author":"Wei","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"17","key":"ioi250012r9","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis.","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"ioi250012r10","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1007\/s11606-020-06073-w","article-title":"Medication utilization for alcohol use disorder in a commercially insured population.","volume":"35","author":"Huskamp","year":"2020","journal-title":"J Gen Intern Med"},{"key":"ioi250012r11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2147\/PPA.S251812","article-title":"Patients\u2019 preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported Medication Preference Questionnaire.","volume":"14","author":"Blackwood","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"ioi250012r14","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/acer.13410","article-title":"Predischarge injectable versus oral naltrexone to improve postdischarge treatment engagement among hospitalized veterans with alcohol use disorder: a randomized pilot proof-of-concept study.","volume":"41","author":"Busch","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"key":"ioi250012r15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.drugalcdep.2014.11.026","article-title":"The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): reliability of substance use and psychiatric disorder modules in a general population sample.","volume":"148","author":"Grant","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"ioi250012r16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.drugalcdep.2009.07.006","article-title":"Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE study.","volume":"105","author":"Ray","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"1-3","key":"ioi250012r19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.drugalcdep.2007.06.001","article-title":"The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of new psychiatric diagnostic modules and risk factors in a general population sample.","volume":"92","author":"Ruan","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"ioi250012r20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/j.1360-0443.2007.02114.x","article-title":"Validation of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).","volume":"103","author":"Humeniuk","year":"2008","journal-title":"Addiction"},{"issue":"1","key":"ioi250012r21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1037\/a0028445","article-title":"The Short Inventory of Problems\u2014Revised (SIP-R): psychometric properties within a large, diverse sample of substance use disorder treatment seekers.","volume":"27","author":"Kiluk","year":"2013","journal-title":"Psychol Addict Behav"},{"issue":"3","key":"ioi250012r22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.drugalcdep.2008.06.005","article-title":"Development of a Readiness Ruler for use with alcohol brief interventions.","volume":"98","author":"Heather","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"ioi250012r23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","article-title":"Psychometric properties of the Penn Alcohol Craving Scale.","volume":"23","author":"Flannery","year":"1999","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"ioi250012r24","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/j.addbeh.2013.01.021","article-title":"Validation of the Drinking Motives Questionnaire (DMQ) in older adults.","volume":"38","author":"Gilson","year":"2013","journal-title":"Addict Behav"},{"issue":"1","key":"ioi250012r25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0306-4603(00)00090-3","article-title":"Sources of motivation for abstinence: a replication analysis of the reasons for quitting questionnaire.","volume":"26","author":"Downey","year":"2001","journal-title":"Addict Behav"},{"issue":"11","key":"ioi250012r26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"10","key":"ioi250012r28","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/dta.3340","article-title":"Consensus for the use of the alcohol biomarker phosphatidylethanol (PEth) for the assessment of abstinence and alcohol consumption in clinical and forensic practice (2022 Consensus of Basel).","volume":"14","author":"Luginb\u00fchl","year":"2022","journal-title":"Drug Test Anal"},{"issue":"6","key":"ioi250012r29","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/1556-4029.13874","article-title":"The PEth blood test in the security environment: what it is; why it is important; and interpretative guidelines.","volume":"63","author":"Ulwelling","year":"2018","journal-title":"J Forensic Sci"},{"issue":"13","key":"ioi250012r30","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"issue":"7","key":"ioi250012r31","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/01.ALC.0000075548.83053.A9","article-title":"A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence.","volume":"27","author":"Balldin","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"ioi250012r32","first-page":"1634","article-title":"Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.","volume":"25","author":"Monti","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"ioi250012r33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jsat.2010.03.005","article-title":"Extended-release naltrexone for treatment of alcohol dependence in primary care.","volume":"39","author":"Lee","year":"2010","journal-title":"J Subst Abuse Treat"},{"key":"ioi250012r34","first-page":"S222","article-title":"Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.","volume":"17","author":"Baser","year":"2011","journal-title":"Am J Manag Care"},{"issue":"5","key":"ioi250012r35","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.2146\/ajhp060648","article-title":"Improving adherence in patients with alcohol dependence: a new role for pharmacists.","volume":"64","author":"Peterson","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"ioi250012r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.112470","article-title":"Correlates of post-hospitalization naltrexone adherence for alcohol use disorder.","volume":"265","author":"Y Bernstein","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"ioi250012r17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","author":"Sobell","year":"1992"},{"key":"ioi250012r1","unstructured":"Chen? CM, Yi? HY, Falk? DE, Stinson? FS, Dawson? DA, Grant? BF. Alcohol use and alcohol use disorders in the United States: main findings from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Accessed October 13, 2022. https:\/\/www.niaaa.nih.gov\/sites\/default\/files\/NESARCDRM.pdf"},{"key":"ioi250012r5","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: summary of national findings. Accessed October 13, 2022. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/Revised2k11NSDUHSummNatFindings\/Revised2k11NSDUHSummNatFindings\/NSDUHresults2011.htm"},{"key":"ioi250012r7","unstructured":"Holt? S. Alcohol use disorder: treatment overview. Accessed October 12, 2022. https:\/\/www.uptodate.com\/contents\/alcohol-use-disorder-treatment-overview"},{"key":"ioi250012r8","unstructured":"McKay? JR. Psychotherapies for substance use disorders. Accessed October 12, 2022. https:\/\/www.uptodate.com\/contents\/substance-use-disorders-psychosocial-management"},{"key":"ioi250012r12","unstructured":"US Centers for Medicare & Medicaid Services. Medicare Part B spending by drug. Accessed January 19, 2023. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-b-spending-by-drug\/data?query=%7B%22filters%22%3A%7B%22rootConjunction%22%3A%7B%22label%22%3A%22And%22%2C%22value%22%3A%22AND%22%7D%2C%22list%22%3A%5B%5D%7D%2C%22keywords%22%3A%22vivitrol%22%2C%22offset%22%3A0%2C%22limit%22%3A10%2C%22sort%22%3A%7B%22sortBy%22%3Anull%2C%22sortOrder%22%3Anull%7D%2C%22columns%22%3A%5B%5D%7D"},{"key":"ioi250012r13","unstructured":"US Centers for Medicare & Medicaid Services. Medicare Part D spending by drug. Accessed January 19, 2023. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-d-spending-by-drug\/data?query=%7B%22filters%22%3A%7B%22rootConjunction%22%3A%7B%22label%22%3A%22And%22%2C%22value%22%3A%22AND%22%7D%2C%22list%22%3A%5B%5D%7D%2C%22keywords%22%3A%22%22%2C%22offset%22%3A8650%2C%22limit%22%3A10%2C%22sort%22%3A%7B%22sortBy%22%3Anull%2C%22sortOrder%22%3Anull%7D%2C%22columns%22%3A%5B%5D%7D"},{"key":"ioi250012r18","unstructured":"World Health Organization. International Guide for Monitoring Alcohol Consumption and Related Harm. Accessed October 13, 2022. https:\/\/www.who.int\/publications\/i\/item\/international-guide-for-monitoring-alcohol-consumption-and-related-harm"},{"key":"ioi250012r27","unstructured":"National Institute on Alcohol Abuse and Alcoholism. COMBINE: Form 90-AIR\/ED (AED ver. B). Accessed October 13, 2022. https:\/\/casaa.unm.edu\/assets\/inst\/appendix-a---economic-form-90.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2832702\/jamainternal_magane_2025_oi_250012_1748025371.39047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T15:01:09Z","timestamp":1748876469000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2832702"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.0522","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}